Citigroup cuts target for Baxter International stock to USD 27.00
Published on 10/06/2026 at 11:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Baxter International stock was trading at EUR 21.57 at Lang & Schwarz on October 6, 2026 at 11:20 a.m. CEST, unchanged from the prior close of EUR 21.57. According to MarketBeat on October 5, 2026, Citigroup lowered its Baxter target from USD 28.00 to USD 27.00 while maintaining a Neutral rating. The latest analyst action puts the focus on execution after a stronger second quarter that also included a one-time benefit.
Citigroup trims its target
The target reduction leaves Citigroup's new USD 27.00 objective above Baxter's prior close in the US market, but the change signals a more cautious near-term view. Baxter's market capitalization was USD 12.5 billion on October 5, 2026, and its 52-week range was USD 15.73 to USD 30.00.
The share price sits between those yearly extremes, while the unchanged EUR 21.57 Lang & Schwarz quote gives German investors a neutral daily reference. The euro quotation and the USD analyst target use different currencies and are therefore not combined into one upside calculation.
Quarterly growth meets one-time help
For the second quarter of 2026, MarketBeat reported adjusted earnings per share of USD 0.56 versus a USD 0.37 consensus and revenue of USD 2.96 billion versus USD 2.80 billion expected. Revenue increased 5.30 percent from the prior-year quarter, creating a quantified comparison behind the current debate over the target.
The second-quarter earnings call carried an important qualification. Fortune reported that adjusted earnings per share fell from USD 0.59 in the prior-year period to USD 0.56, while a USD 0.11 tariff refund supported the quarter. Baxter raised fiscal 2026 adjusted earnings per share guidance from USD 1.85-2.05 to USD 1.95-2.15.
Next report arrives October 29
Yahoo Finance lists October 29, 2026 as Baxter's next earnings date. That report will show whether the second-half outlook can offset the comparison with the tariff-related benefit and support the company's stated fiscal 2026 guidance.
Baxter describes its portfolio as spanning infusion and nutrition, pharmaceuticals, surgical technologies, respiratory devices and connected care. The company also says its products serve hospitals, physician offices and home-care settings, giving the earnings discussion a broad operating base rather than a single-product dependency.
Stock holds at the prior close
At Lang & Schwarz, Baxter International was trading at EUR 21.57 on October 6, 2026 at 11:20 a.m. CEST, unchanged from the prior close of EUR 21.57. The further course of trading is shown by the continuously updated real-time quote of Baxter International stock.
Baxter International stock at a glance
- Company: Baxter International Inc.
- ISIN: US0718131099
- Ticker: BAX
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 6, 2026, 11:20 a.m. CEST: EUR 21.57
- Change versus prior close: 0.00 percent
- Prior close Lang & Schwarz September 30, 2026: EUR 21.57
- Market capitalization: USD 12.5 billion as of October 5, 2026
- 52-week range: USD 15.73-30.00 as of October 5, 2026
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Next earnings date: October 29, 2026
